New hope for kids with tough cancers: scientists test powerful drug trio
NCT ID NCT06006273
Summary
This study aims to find a safe and effective dose of a three-drug combination (eribulin, irinotecan, and temozolomide) for children and young adults with solid tumors that have come back or not responded to other treatments. The main goal is to see how much of the drug eribulin can be given safely alongside the other two drugs. Researchers will also monitor if the treatment helps shrink tumors and provides relief for participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.